US Patent

US12419833 — Injectable triamcinolone formulations

Method of Use · Assigned to Clearside Biomedical Inc · Expires 2040-04-16 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical suspensions of triamcinolone acetonide suitable for administration by suprachoroidal injection through a 30-gauge microneedle.

USPTO Abstract

The present disclosure relates to pharmaceutical suspensions of triamcinolone acetonide, methods of producing such suspensions and methods of using of such suspensions. The pharmaceutical suspensions of the present disclosure are stable and suitable for administration by suprachoroidal injection through a 30-gauge microneedle.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3234 triamcinolone-acetonide

Patent Metadata

Patent number
US12419833
Jurisdiction
US
Classification
Method of Use
Expires
2040-04-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Clearside Biomedical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.